|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||||
  Australasian Journal of DermatologyVolume 44 Issue 2, Pages 106 - 109 Published Online: 30 Apr 2003 Journal compilation © 2010 The Australasian College of Dermatologists
Abstract | References | Full Text: HTML, PDF (Size: 84K) | Related Articles | Citation Tracking  CASE SERIES PUVA treatment of alopecia areata totalis and universalis: A retrospective study Kaley J Whitmont, MB BS. Alan J Cooper, FACD. Submitted 29 May 2000; accepted 24 October 2002. Copyright 2003 Blackwell Publishing Asia Pty Ltd KEYWORDS 8-methoxypsoralen photochemotherapy • psoralen • ultraviolet light Summary
The results of PUVA treatment of alopecia areata (AA) totalis and universalis were reviewed in 26 adult patients. Eight of 15 patients with AA totalis and six of 11 patients with AA universalis achieved a complete response (>90% hair regrowth). Patients with AA totalis had a greater incidence of treatment failure (<25% hair regrowth) than those with AA universalis. Patients with a family history of AA were significantly less likely to have a positive response to PUVA than those with no family history. Sex, age at diagnosis and treatment, interval between diagnosis and treatment, and background of atopy were not significant determinants of outcome. Although unable to show significance for clinical response to treatment, this study demonstrates complete hair regrowth in patients with both AA totalis (53%) and universalis (55%) while reporting a low relapse rate among these patients (21%) within a long period of follow up (mean 5.2 years). Accepted: 24 October 2002; | 
|
